Drug Trial Radar · NCT05353972
Evaluate IMG-007 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Jun 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Jul 5, 2022
Primary completion
May 31, 2023
Study completion May 31, 2023
Sponsor
- Lead sponsor
- Inmagene LLCIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This first in human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK)), and immunogenicity of a single ascending dose of IMG-007 in healthy participants.
Conditions
- Healthy Participants
Interventions
IMG-007 or placeboDrug
intravenously administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Cohort 1 to 5: up to 85 days; Cohort 6 to 7: up to 127 days;
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Linear Clinical Research
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.